Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study

1

Population-based prostate cancer screening reduces cancer-specific mortality but leads to overdiagnosis of clinically insignificant cases.
2

Multiparametric MRI improves detection of clinically significant prostate cancer while decreasing the diagnosis of clinically insignificant cases.
3

The ProScreen trial aims to evaluate prostate cancer mortality as the primary endpoint while minimizing overdiagnosis through targeted biopsies.
4

Interreader variability among pathologists interpreting MRI-targeted biopsies was assessed to understand its impact on the ProScreen trial outcomes.
5

Consensus agreement among pathologists was reached in 65.9% of cases, highlighting significant interobserver variability in grading prostate biopsies.

World Journal Of Urology

by Ronja Hietikko, Tuomas Mirtti, Tuomas P. Kilpeläinen, Teemu Tolonen, Anne Räisänen-Sokolowski, Stig Nordling, Jill Hannus, Marita Laurila, Kimmo Taari, Teuvo L. J. Tammela, Reija Autio, Kari Natunen, Anssi Auvinen, Antti Rannikko
April 6, 2024

1